Drug Trial Radar · NCT07304843
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
207
Actual
Start
Apr 14, 2023
Primary completion
Sep 9, 2026
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Umecrine Cognition ABIndustry
- Sponsor type
- Industry
- First posted
- Dec 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of two dose levels of golexanolone compared with placebo among subjects with a history of non-cirrhotic or Child-Pugh class A cirrhotic Primary Biliary Cholangitis (PBC) with clinically significant fatigue and cognitive symptoms on stable background standard of care (SoC) PBC medication. The objectives of this research study are to assess the safety and tolerability as well the pharmacokinetic (PK) characteristics of golexanolone administered 40 mg BID for 5 days in the target population (part A) and to assess the safety and tolerability, the effects of golexanolone on health-related quality of life (HRQoL), including fatigue, day-time sleepiness and cognitive function as well as Investigator's overall impression of treatment effect of 28 days twice per day (BID) treatment with two dose levels of golexanolone versus placebo (part B).
Conditions
- Primary Biliary Cholangitis (PBC)
Interventions
golexanoloneDrug
soft gelatin capsules, oral dosage twice per day for up to 28 days
golexanoloneDrug
soft gelatin capsules, oral dosage twice a day for up to 28 days
PlaceboDrug
soft gelatin capsules, oral dosage twice a day for up to 28 days
golexanoloneDrug
soft gelatin capsules, oral dosage twice per day for 5 days
PlaceboDrug
soft gelatin capsules, oral dosage twice per day for 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Frequency, intensity, and seriousness of adverse events (AEs) from baseline to Day 28 (part B)Time frame: From enrollment to the end of treatment at 28 days
- Frequency, intensity, and seriousness of adverse events (AEs) from baseline to Day 5 (part A)Time frame: From Baseline to Day 5
Locations
38 sites in 8 countries. Site status is shown where the registry gives one.
University Hospital Düsseldorf
Düsseldorf, Germany
University of Leipzig
Leipzig, Germany
Hippokration General Hospital of Athens
Athens, Greece
University Hospital of Patras
Pátrai, Greece
Facility of CRU Hungary Ltd.
Kistarcsa, Hungary
Università di Milano-Bicocca, S.C. ASST Grande Ospedale Metropolitano Niguarda, Dipartimento di Medicina e Chirurgia, Epatologia e Gastroenterologia
Milan, Italy
University of Padova, Department of Surgery, Oncology and Gastroenterology
Padova, Italy
University Hospital Paolo Giaccone, University of Palermo
Palermo, Italy
A. Gemelli Polyclinic, Sacro Cuore Catholic University
Roma, Italy
Humanitas University
Rozzano, Italy
University of Udine
Udine, Italy
University Medical Center "Zvezdara"
Belgrade, Serbia
Hospital Universitario Parc Taulí
Barcelona, Spain
Hospital Clinic Barcelona
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital 12th October, Madrid
Madrid, Spain
Hospital Universitario Virgen De La Victoria
Málaga, Spain
University Hospital Complex of Pontevedra & IIS Galicia South, Pontevedra
Pontevedra, Spain
University Hospital Marquez de Valdecilla, Santander
Santander, Spain
Virgen del Rocio University Hospital
Seville, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Hacettepe University, Fakulty of Medicine, Department of Gastroenterology and Hepatology
Ankara, Turkey (Türkiye)
9 Eylul University Research and Application Hospital Department of Gastroenterology
Balçova, Turkey (Türkiye)
Dicle University Faculty of Medicine Department of Gastroenterology
Diyarbakır, Turkey (Türkiye)
Ege University Faculty of Medicine, Department of Gastroenterology
Izmir, Turkey (Türkiye)
Kocaeli University Faculty of Medicine Gastroenterology and Hepatology Department
Kocaeli, Turkey (Türkiye)
Recep Tayyip Erdoğan University Training and Research Hospital, Department of Gastroenterology
Rize, Turkey (Türkiye)
Harran Üniversitesi Osmanbey Campus Department of Gastroenterology
Sanliurfa, Turkey (Türkiye)
Karadeniz Technical University, Farabi Hospital, Department of Gastroenterology
Trabzon, Turkey (Türkiye)
NIHR Birmingham BRC
Birmingham, United Kingdom
Glasgow Royal Infirmary
Glasgow, United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas' Hospital, London
London, United Kingdom
Freeman Hospital
Newcastle, United Kingdom
Nottingham Digestive Diseases Centre and Biomedical Research Centre Nottingham University Hospitals NHS Trust, Queen's Medical Centre
Nottingham, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Dept of Gastroenterology & Hepatology Portsmouth Hospitals University NHS Trust Queen Alexandra Hospital
Portsmouth, United Kingdom
Royal Wolverhampton NHS Trust, New Cross Hospital
Wolverhampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.